All In Biotech

Drug Trial Radar · NCT05110976

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

170

Actual

Start

Dec 16, 2021

Primary completion

Aug 2, 2023

Study completion Aug 2, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)

Conditions

  • Asthma

Interventions

  • AZD8630Drug

    Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

  • PlaceboDrug

    Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Number of participants with adverse eventsTime frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)
  2. Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  3. Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  4. Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  5. Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  6. Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  7. Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  8. Part A (IV cohort): Terminal rate constant (λz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  9. Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  10. Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  11. Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  12. Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  13. Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
  14. Part A (IV Cohort): Number of participants with adverse eventsTime frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Tempe, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Glendale, California

  • Research Site

    San Jose, California

  • Research Site

    Homestead, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Boise, Idaho

  • Research Site

    White Marsh, Maryland

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Toledo, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    El Paso, Texas

  • Research Site

    Berlin, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Großhansdorf, Germany

  • Research Site

    Lübeck, Germany

  • Research Site

    Magdeburg, Germany

  • Research Site

    Wiesbaden, Germany

  • Research Site

    Bradford, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Portsmouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.